

Purpose: According to current clinical guidelines, combination therapy of Fenofibrate and statins combination therapy is highly recommended ~~by the current clinical guidelines~~ for treating treatment of mixed dyslipidemia. In this study, we formulated an innovative delayed-release preparation of fenofibrate ~~was designed to reduce the risk of muscle toxicity, caused by simultaneous administration of this combination therapy~~; by altering the pharmacokinetic profile of fenofibrate; ~~as well as~~ and to improve the oral bioavailability of the modified-release formulation.

Comment [A1]: The text alongside has been revised to present the intended meaning in a concise manner by retaining only the information that is essential with respect to context.

Methods: ~~Micronized Fenofibrate was used~~ micronized and used to prepare drug-loaded cores via a ~~powder powder~~ layering process before performing multiparticulate pellet coating. Different coating formulations were screened, and their in vitro release profiles was were compared with those of the commercial sustained-release pellets Lipilfen®. Two optimized formulations were evaluated in

Comment [A2]: A compound modifier contains 2 or more words, which act together as one adjective and are connected by hyphens. Hyphens are used with these terms so that their meaning is understood clearly.

Beagle dog models using and compared with two reference commercial preparations of fenofibrate, Lipanthyl® (the immediate-release preparation) Lipanthyl® and Lipilfen® (the sustained-release pellets Lipilfen®) ~~as references~~.

Comment [A3]: In academic writing, it is important to maintain parallelism in a sentence so that the items being compared can be clearly understood. Here, the sentence has been revised to clearly denote that “in vitro release profiles” are being compared.

Results: The in vivo release of fenofibrate from R1 and R2 (selected from in vitro tests) exhibited a lag phase, which was and then followed by rapid and complete drug release. The relative bioavailabilities of R1 and R2 ~~were~~ (100.4% and 201.1%, respectively), ~~which~~ were higher than that of Lipilfen® (67.2%).

Conclusion: ~~The modified fenofibrate pellets developed~~ showed enhanced bioavailability and delayed-release properties; ~~and They have the potential to~~ can potentially improve safety and compliance when co-~~administered~~ administered with statins. To the best of our knowledge, ~~T~~ this is the first report of a delayed-release preparation of fenofibrate preparation.

Comment [A4]: This phrase was revised to maintain consistency with the phrase used previously in the text (under “Purpose”).